A recent pharmacovigilance study found that when targeted therapies are combined with checkpoint inhibitors, KRAS‐directed agents were most strongly associated with the development of hepatitis, with a significant reporting odds ratio of 3.03 [7]. The gene discussed is KRAS; the disease is Hepatitis.